|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
7
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chaiteerakij R, Yang JD, Harmsen WS,
Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ,
Roberts RO, Olson JE, et al: Risk factors for intrahepatic
cholangiocarcinoma: Association between metformin use and reduced
cancer risk. Hepatology. 57:648–655. 2013. View Article : Google Scholar :
|
|
9
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: Taking away
the candy for cancer? Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Donadon V, Balbi M, Mas MD, Casarin P and
Zanette G: Metformin and reduced risk of hepatocellular carcinoma
in diabetic patients with chronic liver disease. Liver Int.
30:750–758. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ling S, Feng T, Ke Q, Fan N, Li L, Li Z,
Dong C, Wang C, Xu F, Li Y, et al: Metformin inhibits proliferation
and enhances chemosensitivity of intrahepatic cholangiocarcinoma
cell lines. Oncol Rep. 31:2611–2618. 2014.PubMed/NCBI
|
|
12
|
Ling S, Tian Y, Zhang H, Jia K, Feng T,
Sun D, Gao Z, Xu F, Hou Z, Li Y, et al: Metformin reverses
multidrug resistance in human hepatocellular carcinoma Bel 7402/5
fluorouracil cells. Mol Med Rep. 10:2891–2897. 2014.PubMed/NCBI
|
|
13
|
Chiou JF, Tai CJ, Wang YH, Liu TZ, Jen YM
and Shiau CY: Sorafenib induces preferential apoptotic killing of a
drug- and radio-resistant Hep G2 cells through a
mitochondria-dependent oxidative stress mechanism. Cancer Biol
Ther. 8:1904–1913. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saito T, Chiba T, Yuki K, Zen Y, Oshima M,
Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, et al:
Metformin, a diabetes drug, eliminates tumor-initiating
hepatocellular carcinoma cells. PLoS One. 8:e700102013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo Z, Cao M, You A, Gao J, Zhou H, Li H,
Cui Y, Fang F, Zhang W, Song T, et al: Metformin inhibits the
pro-metastatic effect of Sorafenib in hepatocellular carcinoma by
upregulating the expression of TIP30. Cancer Sci. 107:507–513.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Anisimov VN: Metformin for cancer and
aging prevention: Is it a time to make the long story short?
Oncotarget. 6:39398–39407. 2015.PubMed/NCBI
|
|
18
|
Kim JG, Lee SJ, Chae YS, Kang BW, Lee YJ,
Oh SY, Kim MC, Kim KH and Kim SJ: Association between
phosphorylated AMP-activated protein kinase and MAPK3/1 expression
and prognosis for patients with gastric cancer. Oncology. 85:78–85.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martin M and Marais R: Braking BRAF: AMPK
leaves ERK stranded in the desert. Mol Cell. 52:155–156. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baba Y, Nosho K, Shima K, Meyerhardt JA,
Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS,
et al: Prognostic significance of AMP-activated protein kinase
expression and modifying effect of MAPK3/1 in colorectal cancer. Br
J Cancer. 103:1025–1033. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bhat M, Sonenberg N and Gores GJ: The mTOR
pathway in hepatic malignancies. Hepatology. 58:810–818. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dibble CC, Asara JM and Manning BD:
Characterization of Rictor phosphorylation sites reveals direct
regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 29:5657–5670.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao
D, Arojo O, Liu D, Wan L, Zhai B, Yu Y, et al: Sin1 phosphorylation
impairs mTORC2 complex integrity and inhibits downstream Akt
signalling to suppress tumorigenesis. Nat Cell Biol. 15:1340–1350.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li QL, Gu FM, Wang Z, Jiang JH, Yao LQ,
Tan CJ, Huang XY, Ke AW, Dai Z, Fan J, et al: Activation of
PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop
is involved in rapamycin resistance in hepatocellular carcinoma.
PLoS One. 7:e333792012. View Article : Google Scholar
|
|
25
|
Wang C, Cigliano A, Delogu S, Armbruster
J, Dombrowski F, Evert M, Chen X and Calvisi DF: Functional
crosstalk between AKT/mTOR and Ras/MAPK pathways in
hepatocarcinogenesis: Implications for the treatment of human liver
cancer. Cell Cycle. 12:1999–2010. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang H, Peng YF, Ni HM, Li Y, Shi YH, Ding
WX and Fan J: Basal autophagy and feedback activation of Akt are
associated with resistance to metformin-induced inhibition of
hepatic tumor cell growth. PLoS One. 10:e01309532015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gedaly R, Angulo P, Hundley J, Daily MF,
Chen C, Koch A and Evers BM: PI-103 and sorafenib inhibit
hepatocellular carcinoma cell proliferation by blocking
Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res.
30:4951–4958. 2010.PubMed/NCBI
|
|
28
|
Pignochino Y, Dell'Aglio C, Basiricò M,
Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D,
Torchiaro E, et al: The combination of sorafenib and everolimus
abrogates mTORC1 and mTORC2 upregulation in osteosarcoma
preclinical models. Clin Cancer Res. 19:2117–2131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Casadei Gardini A, Marisi G, Scarpi E,
Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti
O, Tamberi S, et al: Effects of metformin on clinical outcome in
diabetic patients with advanced HCC receiving sorafenib. Expert
Opin Pharmacother. 16:2719–2725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nicoletti F, Fagone P, Meroni P, McCubrey
J and Bendtzen K: mTOR as a multifunctional therapeutic target in
HIV infection. Drug Discov Today. 16:715–721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jung CH, Ro SH, Cao J, Otto NM and Kim DH:
mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun K, Guo XL, Zhao QD, Jing YY, Kou XR,
Xie XQ, Zhou Y, Cai N, Gao L, Zhao X, et al: Paradoxical role of
autophagy in the dysplastic and tumor-forming stages of
hepatocarcinoma development in rats. Cell Death Dis. 4:e5012013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H,
Li H, Cui Y, Fang F, Zhang W, et al: Metformin sensitizes sorafenib
to inhibit postoperative recurrence and metastasis of
hepatocellular carcinoma in orthotopic mouse models. J Hematol
Oncol. 9:202016. View Article : Google Scholar : PubMed/NCBI
|
